On January 12, 2023 Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, has been reported granted distribution rights for Caris Life Sciences (Caris)’ molecular profiling services in South East Asia (Press release, Juniper Biologics, JAN 12, 2023, View Source [SID1234626206]). Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Headquartered in the U.S., Caris has built the world’s largest and most informative platform for analysing cancers with the most advanced and comprehensive tumor profiling available, which includes Whole Exome and Whole Transcriptome Sequencing across 22,000+ genes. Caris’ suite of molecular profiling services provides oncologists with clinically important genomic information on key biomarkers and molecular signatures in oncology across all solid tumours.
Raman Singh, Juniper Biologics’ CEO, said: "Through Caris molecular profiling, oncologists are able to recommend improved personalised treatments that specifically target a patients’ cancer. This is a massive development in the advancing of cancer care options, many of which are antiquated and still failing patients. With this targeted approach, we collectively offer patients, especially those with rare or aggressive cancers, a real chance of recovery."
"Caris molecular profiling is the information bridge between tumor biology and cancer treatments, enabling the delivery of precision medicine by helping to illuminate a clearer path in personalized treatment selection for physicians and their patients. Our exclusive partnership with Caris Life Sciences to commercialise and distribute this service in South East Asia will make a real difference in empowering healthcare professionals to make the most informed decisions for their patients."
Andreas Tsukada, Caris Life Sciences’ SVP, President of Japanese Operations and Head of International, said: "We are pleased to partner with Juniper Biologics for the distribution of molecular profiling in South East Asia, further supporting Caris’ goal of improving the lives of as many people as possible. This collaboration provides healthcare professionals the access to best-in-class diagnostic technologies that will enable them to make more precise and individualised treatment decisions for their cancer patients."